Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk
Open Access
- 9 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 101 (21), 1501-1509
- https://doi.org/10.1093/jnci/djp331
Abstract
Müllerian inhibiting substance (MIS) is a member of the transforming growth factor β family of growth and differentiation factors that inhibits elongation and branching of mammary ducts and has been shown to inhibit mammary tumor growth in vitro and in animal models. The objective of this study was to determine whether serum MIS levels are associated with breast cancer risk. We conducted a prospective case–control study of 309 participants who were registered in the Columbia, Missouri Serum Bank. Each of 105 in situ or invasive breast cancer case patients with prediagnostic serum collected before menopause was matched to two control subjects by age, date, menstrual cycle day, and time of day of blood collection. MIS was measured in serum by using an enzyme-linked immunosorbent assay, and estradiol and testosterone concentrations were quantified by using specific radioimmunoassays. Data were analyzed using conditional logistic regression. All tests of statistical significance were two-sided. The relative odds ratio of breast cancer for women in increasing MIS quartiles were 1, 2.8 (95% confidence interval [CI] = 1.0 to 7.4), 5.9 (95% CI = 2.4 to 14.6), and 9.8 (95% CI = 3.3 to 28.9, Ptrend < .001). The association of MIS with breast cancer was weaker in women who were not taking oral contraceptives at the time of blood collection, but adjustment for estradiol and testosterone levels did not materially alter results for these women. The association of MIS with breast cancer did not vary by age at blood collection but was stronger among women who were diagnosed with breast cancer at an older age than among those who were diagnosed at a younger age. MIS may be a novel biomarker of increased breast cancer risk. Additional research including confirmatory epidemiological studies and mechanistic studies is needed.Keywords
This publication has 36 references indexed in Scilit:
- Assay reproducibility and within-person variation of Müllerian inhibiting substanceFertility and Sterility, 2010
- Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell cultureFertility and Sterility, 2008
- Comparison of Ca2+ and CaMKII responses in IVF and ICSI in the mouseMolecular Human Reproduction, 2007
- The Anti-Mullerian hormone and ovarian cancerHuman Reproduction Update, 2007
- The Risk of Breast, Endometrial and Ovarian Cancer in Users of Hormonal PreparationsBasic & Clinical Pharmacology & Toxicology, 2006
- Pilot study investigating the age-related decline in ovarian function of regularly menstruating normal womenFertility and Sterility, 2005
- Müllerian Inhibiting Substance Regulates NFκB Signaling and Growth of Mammary Epithelial Cells in VivoJournal of Biological Chemistry, 2001
- Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated PathwayJournal of Biological Chemistry, 2000
- Serum müllerian-inhibiting substance levels during normal menstrual cyclesFertility and Sterility, 2000
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureJournal of Steroid Biochemistry, 1982